K. Rodriguez-Lorenc

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

P. Fasching, P. Neven, F. Esteva, 2019, The New England journal of medicine.

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

L. Chow, A. Bardia, N. Harbeck, 2019, The New England journal of medicine.

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)

L. Chow, A. Bardia, N. Harbeck, 2020, Therapeutic advances in medical oncology.

Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.

P. Neven, D. Slamon, S. Chia, 2020 .

Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

L. Chow, A. Bardia, N. Harbeck, 2019, Journal of Clinical Oncology.

Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.

P. Neven, G. Hortobagyi, A. Bardia, 2020 .